Organizing pneumonia (OP) is a type of diffuse interstitial lung disease, which may be induced in the context of several clinical conditions, such as drug reactions, infections, autoimmune diseases and cancer. Coronavirus disease 2019 (COVID-19)-associated OP has been reported as a late-stage consequence of the infection or a histological form of COVID-19-associated pneumonia. Autopsies and postmortem lung biopsies have demonstrated that the majority of patients with COVID-19-associated pneumonia develop secondary OP, and COVID-19-associated pneumonia and OP have common radiological features. The diagnosis of COVID-19-associated OP should be suspected in patients with severe acute respiratory syndrome coronavirus 2 infection who exhibit clinical deterioration despite optimal care, or who have aggravating symptoms following an initial recovery. The use of corticosteroids is a typical treatment for OP. However, to date, at least to the best of our knowledge, there are a few reports regarding the role of corticosteroids in COVID-19-associated pneumonia; thus, the optimal time for administration, the dose and treatment duration have not yet been determined. The present study presents two cases of patients with COVID-19, who exhibited clinical deterioration following the initial phase of infection and with radiological characteristics of OP who received corticosteroids and had a favorable outcome. The early diagnosis of COVID-19-associated OP may lead to targeted treatment, decreased requirements for ventilatory support and an improved survival rate.
Radiologically suspected COVID-19-associated organizing pneumonia responding well to corticosteroids: A report of two cases and a review of the literature.
放射学怀疑 COVID-19 相关机化性肺炎对皮质类固醇反应良好:两例病例报告及文献综述
阅读:4
作者:Siafarikas Christos, Stafylidis Christos, Tentolouris Anastasios, Samara Stamatia, Eliadi Irene, Makrodimitri Sotiria, Spandidos Demetrios A, Mathioudakis Nikolaos, Karamichalos Panagiotis, Papalexis Petros, Chlapoutakis Serafeim, Sklapani Pagona, Trakas Nikolaos, Georgakopoulou Vasiliki Epameinondas
| 期刊: | Experimental and Therapeutic Medicine | 影响因子: | 2.300 |
| 时间: | 2022 | 起止号: | 2022 May 18; 24(1):453 |
| doi: | 10.3892/etm.2022.11379 | 研究方向: | 免疫/内分泌 |
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
